<DOC>
	<DOCNO>NCT02754297</DOCNO>
	<brief_summary>In study , peptide receptor radionuclide therapy ( PRRT ) 177Lu-Octreotate ( LuTate ) personalize , i.e . administer activity LuTate tailor patient maximize absorb radiation dose tumor , limit healthy organ . The purpose study : - Assess objective ( radiological ) , symptomatic biochemical response rate follow induction course personalize PRRT ; - Assess overall , disease-specific , progression-free survival follow P-PRRT ; - Correlate therapeutic response survival tumor absorb radiation dose ; - Evaluate acute , subacute chronic adverse event follow P-PRRT ; - Correlate toxicity ( i.e . occurence severity adverse event ) absorb radiation dos organs risk ; - Optimize quantitative SPECT imaging-based dosimetry method subset 20 patient ( sub-study fund Canadian Institutes Health Research ) . This study also compassionate purpose , provide access PRRT patient .</brief_summary>
	<brief_title>Personalized PRRT Neuroendocrine Tumors</brief_title>
	<detailed_description>A prospective , single-center , non-comparative , open phase 2 study . In study , personalize peptide receptor radionuclide therapy ( P-PRRT ) 177Lu-Octreotate ( LuTate ) administer patient progressive and/or symptomatic inoperable neuroendocrine tumor ( NET ) origin express somatostatin receptor . The primary objective ass objective response rate 3 month follow four-cycle induction course P-PRRT assess first 85 participant . This study compassionate aim provide access PRRT patient CHU de Québec - Université Laval center , therefore study pre-determined recruitment period duration limit number participant , may remain open long necessary fulfill aim . The study continue participant complete minimum follow-up 5 year . Interim analyse conduct annually .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Patient suffer progressive and/or symptomatic NET ( site ) ; Patient ineligible , refuse potentially curative treatment surgical resection ; Patient respond , intolerant refuse indicate available palliative treatment ; Demonstration overexpression somatostatin receptor tumor lesion scintigraphic imaging ( Octreoscan 68Ga positron emission tomography . Pregnancy ; Breastfeeding ; . Very limited survival prognosis ( i.e . less week , NET disease condition ) Eastern Cooperative Oncology Group ( ECOG ) 4 performance status ; Inability obtain informed consent participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Personalized</keyword>
	<keyword>Peptide receptor radionuclide therapy</keyword>
	<keyword>PRRT</keyword>
	<keyword>177Lu-DOTATATE</keyword>
	<keyword>177Lu-octreotate</keyword>
</DOC>